HUTCHMED (China) Limited

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HUTCHMED (China) Limited (NASDAQ: HCM) resulting from allegations that HUTCHMED may have issued materially misleading business information to the investing public.

If you purchased HUTCHMED securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased HUTCHMED securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 2, 2022, before trading hours, HUTCHMED announced that the U.S. Food and Drug Administration (FDA) rejected HUTCHMED’s application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.

On this news, HUTCHMED’s American depositary share (ADS) price fell $2.86 per share, or 18%, to close at $12.23 per share on May 2, 2022.

公司名称: HUTCHMED (China) Limited
股票代号: HCM
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。